December 16, 2025 5:13pm

Humpty-Dumpty, Capricor Therapeutics (CAPR -$0.53) dives again <-$4.36 in 6 sessions> <see The Bottom Line>. CAPR should have had a webinar, after announcing their P3 pr, instead of “clueing-in” bankers before INVESTORS! SEC anyone …!!

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trusted and verified intel and share pricing data to bridge the gap to an investment decision

It’s not always time to buy or sell; but it is time to KNOW and why!

Never leave an investor uninformed!  

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!

 

Tuesday’s RMi Pre-opening: Real Econs … https://www.regmedinvestors.com/articles/14231

Monday’s RMi Closing Bell: Suck it up … https://www.regmedinvestors.com

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is PACKING the Pig that’s Broke … https://www.regmedinvestors.com/articles/13812

 

I also, follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

Tuesday: The Dow closed DOWN -302.30 points or -0.62%, the S&P closed DOWN -16.25 points or -0.24 % while the Nasdaq closed UP +54.049 points or +0.23%

  • Theme of the session: delayed jobs figures paint weak picture of economy

Tuesday’s (my) 40-company covered sector’s advance/decline line opened negative with 18 incliners, 19 decliners and s flats ending with a negative close of 17 incliners, 21 decliners and 2 flats

  • Rotation

Henry’omics: We need to more than consider the macro-economic environment to comprehend the micro re “our” universe of cell and gene therapy (C&GT) sector

  • BLS’ November’s jobs report came in better than expected, showing an increase of 64,000 jobs for the month.
  • Economists surveyed predicted that nonfarm payrolls would grow by 45,000 in the period. The BLS reported that October shed 105,000 jobs. The unemployment rate also increased to 4.6%, which was above the forecast for 4.5%, raising concerns about the state of the U.S. economy.

The CBOE Fear (VIX) index closed Tuesday at 16.48 after Monday’s 16.46 following Friday’s 15.81, Thursday’s 14.85, Wednesday’s 15.84 and last Tuesday’s 16.90

 

Metrics: Tuesday …

  • The RUT was down -11.36 points or -0.45%,
  • The XLV was down -2.03 points or -1.30%,
  • The NBI was down -32.27 points or -0.57%;
  • The XBI was down -0.83 points or -0.68%
  • The IWM was down -1.19 or -0.47%;
  • The IBB was down -1.09 points or -0.64%,
  • The VIX was down -0.12 points or -0.02% at to 16.48

 

Q4 – December – 4 positive and 8 negative closes

  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 17) 

  • uniQure NV (QURE +$1.46 after Tuesday’s +$0.60),
  • Supernus Therapeutics (SUPN +$1.04 after Tuesday’s +$0.42 after Friday’s +$0.65),
  • Sarepta Therapeutics (SRPT +$0.76 after Tuesday’s +$0.20),
  • Mesoblast (MESO +$0.58 after Tuesday’s -$0.31),
  • Entrada Therapeutics (TRDA +$0.34),
  • Wave Life Sciences (WVE +$0.30 after Tuesday’s -$0.34),
  • Regenxbio (RGNX +$0.28),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.20) – Who is BUYING this PIG – Ponzi Scheme!
  • Compass Therapeutics (CMPX +$0.16),
  • MiMedx (MCXG +$0.13),

Flat (2)

  • Adverum Biotechnologies ADVM) – acquired
  • Brainstorm Cell Therapeutics (BCLI)

Tuesday’s Closing DOWN (10 of 21): 

  • Arrowhead Pharma (ARWR -$3.79 after Monday’s -$1.51 after Friday’s -$0.73),
  • IQVIA Holdings (IQV -$1.95 after Monday’s +$0.81 after Friday’s -$3.72)
  • Ultragenyx Pharmaceuticals (RARE -$1.89 after Monday’s +$0.18 after Friday’s +$0.03),
  • BioNTech (BNTX -$1.52 after Monday’s -$0.77 after Friday’s -$1.19),
  • Ionis Pharmaceuticals (IONS -$1.39 after Monday’s -$1.21 after Friday’s +$1.68
  • Vericel (VCEL -$0.99),
  • Vertex (VRTX +$0.75 after Monday’s +$3.57 after Friday’s +$6.11
  • Cellectis SA (CLS -$0.73),
  • Capricor Therapeutics (CAPR -$0.53 after Monday’s +$0.64 after Friday’s -$1.16),
  • AxoGen (AXGN -$0.43 after Monday’s -$0.38 after Friday’s +$0.41),

 

The Bottom Line: More of the … WHYs

Back on the merry-go-round … “the Dow and S&P 500 slumped as investors saw a mixed picture from updates on the labor market. The delayed November jobs report showed an uptick in jobs added last month but also found the unemployment rate jumped to a 2021 high.”

  • The report will add fuel to the fire on the big year-end debate over whether the Federal Reserve will halt or hasten policy easing in 2026. A plurality of traders is betting on two rate cuts from the Fed next year, as policymakers focus on tackling the labor market rather than dealing with sticky inflation.
  • The jobs data sets the stage for another release on Thursday, with consumer inflation numbers for November set for an unveiling. Together, the two reports make up a chunk of the "great deal of data" Fed Chair Jerome Powell has flagged the central bank will study before its next rate decision in January. <Yahoo Finance>

Most C&GT sector equities Tuesday declined followed Monday after Friday and Thursday’s declines after inclining Wednesday then declining on Tuesday, follow-by positive closes on Monday, then last Friday’s dive, Thursday and Wednesday positive closes following negative closes on the previous Tuesday and Monday.

 

Maintaining MY opinion (from title): Capricor Therapeutics (CAPR) is overvalued, overbought and headed to a BIG slide … I would also ask if the SEC should investigate the post news run-up and the sudden offering financing pricing … 12/2 pricing, $6.36, offering price of $25.00 to today’s -$0.53 to $26.02?

  • Desperate times influence a “sudden” webinar!
  • CAPR should have had a webinar, after announcing their P3 pr, instead of “clueing-in” bankers before INVESTORS! SEC anyone …!!
  • I believe CAPR will get some “friendly” brokers to BUY yet how long will those last???

Not anyone else is on the same page:

  • Remaining risks are tied to HOPE-3 and potential priority review dynamics
  • Make your own decision to CUT-BACK as regulatory moving pieces will shape the investment narrative
  • Investors may wish to stay informed to better track and interpret future shifts in CAPR's soon
  • to be evolving story – can you afford to wait and possibly take a hit out-of-the-blue.

 

Take it a session at a time … the REAL question is … how long will this sentiment and conviction “run” last in the “clean-out-the-exposure” December?

  • A question does NOT answer an inquiry; investors need more than a few catalysts that could revive a rally, I do NOT expect end end-of-year flurry! Depleted market valuations and the uncertain payoff from heavy spending as we get closer to 2025 ends and then coming Q4 and FY25 financial and achievement results

 

3rd week of December:

  • 12/16- Tuesday closed negative with 17 positive, 21 negative and 2 flats
  • 12/15 – Monday closed negative with 15 positive, 23 negative and 2 flats

2nd December week:

  • 12/12 – Friday closed negative with 12 positive, 26 negative and 2 flats
  • 12/11 – Thursday closed negative with 18 positive, 19 negative and 3 flats
  • 12/10 – Wednesday closed positive with 24 positive, 12 negative and 4 flats
  • 12/9 - Tuesday closed negative with 10 positive, 27 negative and 3 flats
  • 12/8 - Monday closed positive with 22 positive, 16 negative and 2 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Welcome to my world of defining the “grey’ in our universe!

•              I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

•              “I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!”

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:   

  • Tuesday: uniQure NV (QURE), Supernus Therapeutics (SUPN), and Sarepta Therapeutics (SRPT)
  • Monday: Vertex (VRTX), IQVIA Holdings (IQV) and Moderna (MRNA)
  • Friday: Vertex (VRTX), Regenxbio (RGNX) and Supernus Therapeutics (SUPN)

The worst three (3) in the session:

  • Tuesday: Arrowhead Pharma (ARWR), IQVIA Holdings (IQV) and Ultragenyx Pharmaceuticals (RARE)
  • Monday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharma (ARWR) and Ionis Pharmaceuticals (IONS)
  • Friday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Arrowhead Pharma (ARWR)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.